Abstract
The review focuses on relapse and refractory forms of acute myeloid leukemia, which is a heterogeneous disease and does not have a single universal therapeutic scheme. The paper presents the characteristics of protocols with inclusion of new agents, shows the role of allogenic hematopoietic stem cell transplantation and advances in risk stratification for the treatment for acute myeloid leukemia. The prospects of the therapy personalization based on molecular tests have been determined. The application of more effective induction and post-remission protocols shows a guaranteed reduction in the relapse rate.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
